Classification and Detection of Mesothelioma Cancer Using Feature Selection-Enabled Machine Learning Technique
Biomed Res Int. 2022 Jul 27;2022:9900668. doi: 10.1155/2022/9900668. eCollection 2022.ABSTRACTCancer of the mesothelium, sometimes referred to as malignant mesothelioma (MM), is an extremely uncommon form of the illness that almost always results in death. Chemotherapy, surgery, radiation therapy, and immunotherapy are all potential treatments for multiple myeloma; however, the majority of patients are identified with the disease at an advanced stage, at which time it is resistant to these therapies. After obtaining a diagnosis of advanced multiple myeloma, the average length of time that a person lives is one year after h...
Source: Biomed Res - August 8, 2022 Category: Research Authors: M Shobana V R Balasraswathi R Radhika Ahmed Kareem Oleiwi Sushovan Chaudhury Ajay S Ladkat Mohd Naved Abdul Wahab Rahmani Source Type: research

Malignant peritoneal mesothelioma
We present a report of a rare case of a 67-year-old male patient with MPM and severe abdominal pain, bloating, and bloody ascites as manifestations. The diagnosis was confirmed by cytology of ascites aspiration fluid and further verified by laparoscopic exploratory biopsy. The characteristics of signs and clinical manifestations in this case are less common. As everyone knows, asbestos exposure is usually associated with pleural mesothelioma, but only 6%-10% of malignant mesothelioma cases originate from the peritoneum, which is far less than pleural mesothelioma. Generally, its non-specificity provides a huge challenge to...
Source: The American Journal of the Medical Sciences - August 8, 2022 Category: General Medicine Authors: Cai-Pu Chun Lin-Xie Song Hong-Pan Zhang Dan-Dan Guo Gui-Xuan Xu Ya Li Xin Xin Jiachen Cao Feng Li Source Type: research

Classification and Detection of Mesothelioma Cancer Using Feature Selection-Enabled Machine Learning Technique
Biomed Res Int. 2022 Jul 27;2022:9900668. doi: 10.1155/2022/9900668. eCollection 2022.ABSTRACTCancer of the mesothelium, sometimes referred to as malignant mesothelioma (MM), is an extremely uncommon form of the illness that almost always results in death. Chemotherapy, surgery, radiation therapy, and immunotherapy are all potential treatments for multiple myeloma; however, the majority of patients are identified with the disease at an advanced stage, at which time it is resistant to these therapies. After obtaining a diagnosis of advanced multiple myeloma, the average length of time that a person lives is one year after h...
Source: Biomed Res - August 8, 2022 Category: Research Authors: M Shobana V R Balasraswathi R Radhika Ahmed Kareem Oleiwi Sushovan Chaudhury Ajay S Ladkat Mohd Naved Abdul Wahab Rahmani Source Type: research

Malignant peritoneal mesothelioma
We present a report of a rare case of a 67-year-old male patient with MPM and severe abdominal pain, bloating, and bloody ascites as manifestations. The diagnosis was confirmed by cytology of ascites aspiration fluid and further verified by laparoscopic exploratory biopsy. The characteristics of signs and clinical manifestations in this case are less common. As everyone knows, asbestos exposure is usually associated with pleural mesothelioma, but only 6%-10% of malignant mesothelioma cases originate from the peritoneum, which is far less than pleural mesothelioma. Generally, its non-specificity provides a huge challenge to...
Source: The American Journal of the Medical Sciences - August 8, 2022 Category: General Medicine Authors: Cai-Pu Chun Lin-Xie Song Hong-Pan Zhang Dan-Dan Guo Gui-Xuan Xu Ya Li Xin Xin Jiachen Cao Feng Li Source Type: research

ASO Author Reflections: Co-Localization of Synchronous Gastrointestinal Stromal Tumors (GISTs) and Peritoneal Mesothelioma (PM): A Case Series
Ann Surg Oncol. 2022 Aug 5. doi: 10.1245/s10434-022-12339-w. Online ahead of print.NO ABSTRACTPMID:35930107 | DOI:10.1245/s10434-022-12339-w (Source: Ann Oncol)
Source: Ann Oncol - August 5, 2022 Category: Cancer & Oncology Authors: Asimina S Courelli Ashwyn K Sharma Jason K Sicklick Source Type: research

ASO Author Reflections: Co-Localization of Synchronous Gastrointestinal Stromal Tumors (GISTs) and Peritoneal Mesothelioma (PM): A Case Series
Ann Surg Oncol. 2022 Aug 5. doi: 10.1245/s10434-022-12339-w. Online ahead of print.NO ABSTRACTPMID:35930107 | DOI:10.1245/s10434-022-12339-w (Source: Ann Oncol)
Source: Ann Oncol - August 5, 2022 Category: Cancer & Oncology Authors: Asimina S Courelli Ashwyn K Sharma Jason K Sicklick Source Type: research

Cancers, Vol. 14, Pages 3813: An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma
hon C. Arnold Mesothelioma is an aggressive cancer with limited treatment options and a poor prognosis. Phytocannabinoids possess anti-tumour and palliative properties in multiple cancers, however their effects in mesothelioma are unknown. We investigated the anti-cancer effects and potential mechanisms of action for several phytocannabinoids in mesothelioma cell lines. A panel of 13 phytocannabinoids inhibited growth of human (MSTO and H2452) and rat (II-45) mesothelioma cells in vitro, and cannabidiol (CBD) and cannabigerol (CBG) were the most potent compounds. Treatment with CBD or CBG resulted in G0/G1 arrest, dela...
Source: Cancers - August 5, 2022 Category: Cancer & Oncology Authors: Emily K. Colvin Amanda L. Hudson Lyndsey L. Anderson Ramyashree Prasanna Kumar Iain S. McGregor Viive M. Howell Jonathon C. Arnold Tags: Article Source Type: research

ASO Author Reflections: Co-Localization of Synchronous Gastrointestinal Stromal Tumors (GISTs) and Peritoneal Mesothelioma (PM): A Case Series
(Source: Annals of Surgical Oncology)
Source: Annals of Surgical Oncology - August 5, 2022 Category: Cancer & Oncology Source Type: research

Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health
BRCA-1 associated protein 1 (BAP1) tumour predisposition syndrome (TPDS) is a hereditary condition characterised by germline mutation of the tumour suppressor BAP1. This disorder is associated with the development of various benign and malignant tumours, mainly involving the skin, eyes, kidneys, and mesothelium. In this article, we report the case of a man recruited through the Apulia (Southern Italy) Mesothelioma Regional Operational Centre of the National Register of Mesotheliomas, who suffered from uveal melanoma, renal cancer, and mesothelioma, and a familial cluster of BAP1 germline mutations demonstrated by molecular...
Source: Frontiers in Oncology - August 4, 2022 Category: Cancer & Oncology Source Type: research

GSE183088 TRIM28 keeps the time of mitotic gene expression sustaining proliferation and progression of Malignant Pleural Mesothelioma (MPM).
Contributor : Alessia CiarrocchiSeries Type : Expression profiling by arrayOrganism : Homo sapiensRNA extracted from tumor samples of 86 patients affected by MPM was analyzed on the nCounter system using a custom panel called MPM_C9073 (Nanostring Technologies). (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - August 3, 2022 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research

Tumor suppressor effect of an antibody on xenotransplanted sarcomatoid mesothelioma cells
ConclusionsAX10 could have therapeutic potential for patients with sarcomatoid mesothelioma. (Source: Thoracic Cancer)
Source: Thoracic Cancer - August 2, 2022 Category: Cancer & Oncology Authors: Masayoshi Hasegawa, Yuki Hanamatsu, Chiemi Saigo, Yusuke Kito, Tamotsu Takeuchi Tags: ORIGINAL ARTICLE Source Type: research

Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review
ConclusionThis review provides detailed information about the characteristics of PPK models of anti-PD-1 mAbs, the effects of covariates on PK parameters, and the current status of the application of the models. ALB, BW, specific tumor type, sex, and PS should be considered for the future development of the PPK model of anti-PD-1 mAbs. Other potential covariates that were assessed less frequently but still have significance (e.g., LDH, IgG, and IPICO) should not be ignored. Thus, further research and thorough investigation are needed to assess new or potential covariates, which will pave the way for personalized anti-PD-1 ...
Source: Frontiers in Immunology - August 2, 2022 Category: Allergy & Immunology Source Type: research

Cancers, Vol. 14, Pages 3758: Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today?
ck Dorn MPM is an aggressive tumor originating from pleural mesothelial cells. A characteristic feature of the disease is the dominant prevalence of therapeutically intractable inactivating alterations in TSGs, making MPM one of the most difficult cancers to treat and the epitome of a cancer characterized by a significant lack of therapy options and an extremely poor prognosis (5-year survival rate of only 5% to 10%). Extensive interpatient heterogeneity poses another major challenge for targeted therapy of MPM, warranting stratified therapy for specific subgroups of MPM patients. Accurate preclinical models are critic...
Source: Cancers - August 2, 2022 Category: Cancer & Oncology Authors: Yanyun Gao Marianna Kruithof-de Julio Ren-Wang Peng Patrick Dorn Tags: Review Source Type: research

From Immunosuppression to Immunomodulation - Turning Cold Tumours into Hot
J Cancer. 2022 Jul 4;13(9):2884-2892. doi: 10.7150/jca.71992. eCollection 2022.ABSTRACTCancer cells employ various mechanisms to evade and suppress anti-cancer immune responses generating a "cold" immunosuppressive tumour microenvironment. Oncolytic viruses are a promising tool to convert tumour immunosuppression to immunomodulation and improve the efficacy of cancer treatment. Emerging preclinical and clinical findings confirm that oncolytic viruses act in a multimodal scheme, triggering lyses, immunogenic cell death and finally inducing anti-cancer immune responses. In this paper, we tested the local administration of a ...
Source: Cancer Control - August 1, 2022 Category: Cancer & Oncology Authors: Mariangela Garofalo Katarzyna Wanda Pancer Magdalena Wieczorek Monika Staniszewska Stefano Salmaso Paolo Caliceti Lukasz Kuryk Source Type: research

Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
AbstractMalignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in many countries, the incidence of malignant pleural mesothelioma failed to decline worldwide. While little progress has been made in malignant pleural mesothelioma diagnosis, bevacizumab at first, then followed by double immunotherapy (nivolumab plus ipilumumab), were all shown to improve survival in large phase III randomized trials. The morphological analysis of the histological subtyping remains the primary indicator for th...
Source: Targeted Oncology - July 30, 2022 Category: Cancer & Oncology Source Type: research